44 reports of this reaction
1.9% of all DANTROLENE SODIUM reports
#12 most reported adverse reaction
MUSCULAR WEAKNESS is the #12 most commonly reported adverse reaction for DANTROLENE SODIUM, manufactured by Endo USA, Inc.. There are 44 FDA adverse event reports linking DANTROLENE SODIUM to MUSCULAR WEAKNESS. This represents approximately 1.9% of all 2,376 adverse event reports for this drug.
Patients taking DANTROLENE SODIUM who experience muscular weakness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MUSCULAR WEAKNESS is a less commonly reported adverse event for DANTROLENE SODIUM, but still significant enough to appear in the safety profile.
In addition to muscular weakness, the following adverse reactions have been reported for DANTROLENE SODIUM:
The following drugs have also been linked to muscular weakness in FDA adverse event reports:
MUSCULAR WEAKNESS has been reported as an adverse event in 44 FDA reports for DANTROLENE SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MUSCULAR WEAKNESS accounts for approximately 1.9% of all adverse event reports for DANTROLENE SODIUM, making it a notable side effect.
If you experience muscular weakness while taking DANTROLENE SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.